CN108024959A - 用于治疗乳腺病症的经乳头方法和组合物 - Google Patents
用于治疗乳腺病症的经乳头方法和组合物 Download PDFInfo
- Publication number
- CN108024959A CN108024959A CN201680052914.XA CN201680052914A CN108024959A CN 108024959 A CN108024959 A CN 108024959A CN 201680052914 A CN201680052914 A CN 201680052914A CN 108024959 A CN108024959 A CN 108024959A
- Authority
- CN
- China
- Prior art keywords
- composition
- breast
- vitamin
- carcinoma
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Materials For Medical Uses (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192505P | 2015-07-14 | 2015-07-14 | |
| US62/192,505 | 2015-07-14 | ||
| PCT/US2016/042202 WO2017011623A1 (en) | 2015-07-14 | 2016-07-14 | Transpapillary methods and compositions for treating breast disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108024959A true CN108024959A (zh) | 2018-05-11 |
Family
ID=57757662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680052914.XA Pending CN108024959A (zh) | 2015-07-14 | 2016-07-14 | 用于治疗乳腺病症的经乳头方法和组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180200206A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3322406A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018520182A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108024959A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016294526A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2992282A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017011623A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| EP3283061A4 (en) * | 2015-04-14 | 2019-04-17 | Atossa Genetics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES |
| EP3679061A4 (en) * | 2017-09-06 | 2021-06-09 | University of Cincinnati | METHOD OF PREDICTING BREAST LESIONS IN EARLY STAGE |
| EP3681491A4 (en) | 2017-09-11 | 2021-06-30 | Atossa Therapeutics, Inc. | PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES |
| CN110221068B (zh) * | 2018-03-02 | 2020-09-18 | 中国医学科学院基础医学研究所 | 检测Kyn含量的试剂的应用 |
| WO2021003433A1 (en) | 2019-07-03 | 2021-01-07 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040030248A1 (en) * | 2002-03-19 | 2004-02-12 | Cytyc Health Corporation | Intraductal management of breast lesions involving therapeutic or diagnostic agents |
| US20040092894A1 (en) * | 1999-03-01 | 2004-05-13 | Cytyc Health Corporation | Apparatus, methods and kits for simulaneous delivery of a substance to multiple breast milk ducts |
| US20040208830A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
| CN1917910A (zh) * | 2003-12-23 | 2007-02-21 | Cytyc公司 | 用于进入乳腺管以执行医疗程序的医疗器械及其方法 |
| US20100112041A1 (en) * | 2006-11-21 | 2010-05-06 | Jina Pharmaceuticals, Inc. | Endoxifen Compositions And Methods |
| US20120010245A1 (en) * | 2008-12-11 | 2012-01-12 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising a serm |
| US20140088059A1 (en) * | 2012-07-13 | 2014-03-27 | South Dakota State University | Compositions and Methods for Localized Drug Delivery through Mammary Papillae |
| CN104203961A (zh) * | 2012-03-05 | 2014-12-10 | 泽维尔大学 | 作为用于乳腺癌的治疗的基于硼的4-羟基他莫昔芬和因多昔芬前药 |
| WO2015106094A1 (en) * | 2014-01-10 | 2015-07-16 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6881548B2 (en) * | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| US20020117169A1 (en) * | 2001-02-27 | 2002-08-29 | Kurz Daniel R. | Cover and applicator for a portion of a mammalian body |
| JP2004530659A (ja) * | 2001-02-28 | 2004-10-07 | ジャイルズ,ブライアン,シー. | 抗腫瘍および抗転移作用のための方法および処方 |
| KR100419298B1 (ko) * | 2003-07-28 | 2004-02-18 | 조규학 | 부착형 브래지어 및 그 제조방법 |
| US20050142315A1 (en) * | 2003-12-24 | 2005-06-30 | Desimone Joseph M. | Liquid perfluoropolymers and medical applications incorporating same |
| IL177006A0 (en) * | 2005-08-02 | 2006-12-10 | Veridex Llc | Predicting bone relapse of breast cancer |
| WO2007067773A2 (en) * | 2005-12-09 | 2007-06-14 | Mayo Foundation For Medical Education And Research | Assessing outcomes for breast cancer patients by determining cyp2d6 genotype |
| ES2539042T3 (es) * | 2006-06-02 | 2015-06-25 | Glaxosmithkline Biologicals S.A. | Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia |
| CA2673870A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| WO2009105640A1 (en) * | 2008-02-22 | 2009-08-27 | Virginia Commonwealth University | Signatures associated with rejection or recurrence of cancer |
| WO2010008427A1 (en) * | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
| WO2009129352A2 (en) * | 2008-04-15 | 2009-10-22 | Windy Hill Medical | Device and method for accessing and treating ducts of mammary glands |
| WO2010009335A1 (en) * | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2011072244A1 (en) * | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
| EP2425833A1 (de) * | 2010-09-03 | 2012-03-07 | Fresenius Kabi Deutschland GmbH | Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie |
| US20130045179A1 (en) * | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
| US9517183B2 (en) * | 2012-01-30 | 2016-12-13 | Patrick B. Ward | Nipple abrasion protector |
| EP3283061A4 (en) * | 2015-04-14 | 2019-04-17 | Atossa Genetics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES |
-
2016
- 2016-07-14 CA CA2992282A patent/CA2992282A1/en not_active Abandoned
- 2016-07-14 US US15/744,004 patent/US20180200206A1/en not_active Abandoned
- 2016-07-14 JP JP2018501348A patent/JP2018520182A/ja active Pending
- 2016-07-14 EP EP16825155.1A patent/EP3322406A4/en not_active Withdrawn
- 2016-07-14 AU AU2016294526A patent/AU2016294526A1/en not_active Abandoned
- 2016-07-14 WO PCT/US2016/042202 patent/WO2017011623A1/en not_active Ceased
- 2016-07-14 CN CN201680052914.XA patent/CN108024959A/zh active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040092894A1 (en) * | 1999-03-01 | 2004-05-13 | Cytyc Health Corporation | Apparatus, methods and kits for simulaneous delivery of a substance to multiple breast milk ducts |
| US20040030248A1 (en) * | 2002-03-19 | 2004-02-12 | Cytyc Health Corporation | Intraductal management of breast lesions involving therapeutic or diagnostic agents |
| US20040208830A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
| CN1917910A (zh) * | 2003-12-23 | 2007-02-21 | Cytyc公司 | 用于进入乳腺管以执行医疗程序的医疗器械及其方法 |
| US20100112041A1 (en) * | 2006-11-21 | 2010-05-06 | Jina Pharmaceuticals, Inc. | Endoxifen Compositions And Methods |
| US20120010245A1 (en) * | 2008-12-11 | 2012-01-12 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising a serm |
| CN104203961A (zh) * | 2012-03-05 | 2014-12-10 | 泽维尔大学 | 作为用于乳腺癌的治疗的基于硼的4-羟基他莫昔芬和因多昔芬前药 |
| US20140088059A1 (en) * | 2012-07-13 | 2014-03-27 | South Dakota State University | Compositions and Methods for Localized Drug Delivery through Mammary Papillae |
| WO2015106094A1 (en) * | 2014-01-10 | 2015-07-16 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
Non-Patent Citations (3)
| Title |
|---|
| KAUSHALKUMAR DAVE ET AL.: "Transpapillary Drug Delivery to the Breast", 《PLOS ONE》 * |
| LAY MING LEE ET AL.: "In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple)", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 * |
| MARTIN C.DYCK ET AL: "The anticancer effects of Vitamin D and omega-3 PUFAs in combination via cod-liver oil: One plus one may equal more than two", 《MED HYPOTHESES》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016294526A1 (en) | 2018-02-08 |
| JP2018520182A (ja) | 2018-07-26 |
| EP3322406A1 (en) | 2018-05-23 |
| WO2017011623A1 (en) | 2017-01-19 |
| CA2992282A1 (en) | 2017-01-19 |
| US20180200206A1 (en) | 2018-07-19 |
| EP3322406A4 (en) | 2019-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rizzoli et al. | Cancer-associated bone disease | |
| ES2991315T3 (es) | Métodos y composiciones relacionados con el antagonismo del receptor de glucocorticoides y con el cáncer de próstata | |
| Paridaens et al. | Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer | |
| EP3797770B1 (en) | Softgel capsule comprising apalutamide | |
| JP2018520182A (ja) | 乳房障害を処置するための経乳頭方法及び組成物 | |
| Brown et al. | Denosumab in patients with cancer—a surgical strike against the osteoclast | |
| Love et al. | A feasibility study of the intraductal administration of chemotherapy | |
| Kataja et al. | Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | |
| WO2000043038A1 (en) | Methods and devices for delivery of agents to breast milk ducts | |
| Dixon et al. | Lessons from the use of aromatase inhibitors in the neoadjuvant setting. | |
| KR20200103764A (ko) | 유방 장애의 관내 치료 방법 | |
| US20260041695A1 (en) | Combination therapies for treatment of breast cancer | |
| Boers et al. | Serial [18F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer | |
| US20160375234A1 (en) | Transpapillary methods and compositions for diagnosing and treating breast conditions | |
| Lan et al. | Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers | |
| Strube et al. | Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption | |
| TW201600086A (zh) | 用於治療三陰性乳癌之維利帕尼(veliparib)與卡鉑之組合 | |
| Wang et al. | The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR | |
| HK1255302A1 (en) | Transpapillary methods and compositions for treating breast disorders | |
| WO2015166355A2 (en) | Targeted therapy to restore radioactive iodine transport in thyroid cancer | |
| Reddy et al. | Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer | |
| Mucha et al. | Patient with liver epithelioid hemangioendothelioma treated by transplantation: 3 years’ observation | |
| Biswas | Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report | |
| JP2025535957A (ja) | がんの特定および/または治療 | |
| Nicolini et al. | Final Results of a 2: 1 Control Case Observational Study with Interferon Beta and Interleukin-2 in Addition to First-Line Hormone Therapy in ER+ Endocrine Responsive Metastatic Breast Cancer Patients. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1255302 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Washington State Applicant after: Atosa therapeutics Address before: Washington State Applicant before: ATOSSA GENETICS, Inc. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180511 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1255302 Country of ref document: HK |